Expertise in
1
conditions

Diego M. Cecchini

B, AR 
Expertise in
1
conditions
B, AR 

Overview

Diego Cecchini practices practicing medicine in Argentina.

Mr. Cecchini is highly rated in 1 condition, according to our data. His clinical expertise encompasses HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Meningitis, and COVID-19.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

B, Argentina
Other Locations
Argerich, B, Argentina
Cosme, X, Argentina
Almirante Brown, B, Argentina
Muniz, B, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants
Enrollment Status: Active_not_recruiting
Publish Date: April 21, 2026
Intervention Type: Drug
Study Drugs: Atazanavir, Darunavir, Cobicistat, Background regimen
Study Phase: Phase 2/Phase 3

55 Total Publications

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.
Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.
Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
Published: June 16, 2026

Frequently Asked Questions about Diego M. Cecchini

Is Diego M. Cecchini a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Diego M. Cecchini is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Diego M. Cecchini participate in research or clinical trials?

Yes. Diego M. Cecchini has published 55 articles and abstracts on conditions like HIV/AIDS. You can view a list of Diego M. Cecchini's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cecchini's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile